Cancer

Immunotherapies for head and neck cancer:
To develop new cancer therapies by studying how the immune system, by way of neo-antigens, can recognize and eliminate tumor cells by targeting molecules only found on the surface of the tumor cells.

The research is part of the Immuno-Oncology Translational Network, which was established as part of the National Cancer Institute’s Cancer Moonshot program. A collaboration with the UC San Diego Moores Cancer Center and LJI Professor Stephen Schoenberger, Ph.D.

In a collaboration with Vanderbilt University researchers, the Peters lab is also comparing data from MHC ligand elution experiments, in silicon predictions, and experimental T cell recognition assays to determine what drives immune recognition in head and neck cancers

Pipeline tool to predict immunogenicity of cancer neo-epitopes:
Research to provide in-depth characterization of the importance of several variables affecting cancer neo-epitope immunogenicity. These findings in turn will allow the development of bioinformatic tools, and a unified analysis pipeline, towards the identification of cancer neo-epitopes. Identification of such epitopes is expected to allow quick identification of cancer-associated, patient-specific, mutations potentially recognized as epitopes, with direct applicability to the development of efficacious therapeutics.

NIH/NCI (5R21AI134127).

About La Jolla Institute

The La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease. Visit lji.org for more information.

Share this Article:

LJI Professor Sujan Shresta, Ph.D., is a leader in dengue virus research and vaccine development
LJI and Synbal, Inc. scientists develop new tool for pandemic preparedness